Aim: Genetic investigation of human plasma lipidome to get insights into lipid-related disorders beyond traditional lipid measures. Methods and Results: We performed a genome-wide association study (GWAS) of 141 lipid species (n=2,181 individuals), followed by phenome-wide scans (PheWAS) with 44 clinical endpoints related to cardiometabolic, psychiatric and gastrointestinal disorders (n=456,941 individuals). SNP-based heritability for lipid species ranged from 0.10-0.54. Lipids with long-chain polyunsaturated fatty acids showed higher heritability and genetic sharing, suggesting considerable genetic regulation at acyl chains levels. We identified 35 genomic regions associated with at least one lipid species (P<5x10 -8 ), revealing 37 new SNP-lipid species pair associations e.g. new association between ABCG5/8 and CE(20:2;0). PheWAS of lipid-species-associated loci suggested new associations of BLK with obesity, FADS2 with thrombophlebitis, and BLK and SPTLC3 with gallbladder disease (false discovery rate <0.05). The association patterns of lipid-species-associated loci supplied clues to their probable roles in lipid metabolism e.g. suggestive role of SYNGR1, MIR100HG, and PTPRN2 in desaturation and/or elongation of fatty acids. At known lipid loci (FADS2, APOA5 and LPL), genetic associations provided detailed insights to their roles in lipid biology and diseases. We also show that traditional lipid measures may fail to capture lipids such as lysophospatidylcholines (LPCs) and phosphatidylcholines (PCs) that are potential disease risk factors, but are not included in routine screens. The full genome-wide association statistics are available on the web-based database (http://35.205.141.92).
Introduction
Plasma lipids are risk factors for various complex disorders like cardiovascular disease (CVD) and type 2 diabetes. 1, 2 Low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, lipoprotein (a), total triglycerides and total cholesterol are "traditional lipid measures" routinely used to dissect dyslipidemia and risks for diseases. Human plasma comprises of hundreds of chemically and functionally diverse molecular lipid species, 3 which are not captured in everyday, clinical lipid analysis. Lipid species belonging to cholesterol esters (CE), lysophosphatidylcholines (LPC), phosphatidylcholines (PC), phosphatidylethanolamines (PE), ceramides (CER), sphingomyelins (SM), and triacylglycerols (TAG) species have been shown to improve risk assessment over traditional lipid measures and other risk factors for type 2 diabetes and CVD events. [4] [5] [6] [7] [8] [9] Moreover, the fatty acid compositions of phospholipids have been implicated in coronary heart disease beyond traditional lipid measures. 10 Genetic screens have identified over 250 genomic loci associated with traditional lipid levels. 11, 12 These genetic findings have helped to understand lipid biology and physiological processes underlying CVD and other diseases. For the majority of the genomic loci, however, the causal genes and/or their effects on detailed lipidomes beyond traditional lipid measures are unknown. Only a few studies have reported genetic associations for lipid species either through studies on subsets of the lipidome 13, 14 or GWASs on metabolomic measures. [15] [16] [17] [18] [19] [20] In most of these studies, however, the lipids have not been resolved on the molecular level of fatty acid or acyl chain composition (molecular lipid species).
We considered that the genetic investigation of detailed lipidomic profiles could provide better insight into lipid metabolism and its link to clinical outcomes surpassing traditional lipid measures. To test this, we carried out a GWAS of lipidomic profiles of 2,181 individuals followed by PheWAS with 44 clinical end-points related to cardiometabolic, psychiatric and gastro-intestinal disorders in an independent dataset of 456,941 individuals from the Finnish and UK Biobanks ( Figure 1 ). We aimed to identify genomic loci influencing plasma levels of lipid species and their effects on the risk of diseases. We also set out to answer the following questions: (1) how heritable are the lipid species and do they share genetic components (2) can we gain mechanistic insights to pathways linking genetic variation to disease risk through detailed measures of the lipid species and (3) could detailed lipid profiles provide additional biological insights to genetic regulation of lipid metabolism for the previously identified lipid loci.
Methods

Study cohorts
The detailed description of the subject recruitment and measurements is provided in Supplementary Data. Briefly, the study included participant from the following cohorts:
EUFAM: The European Multicenter Study on Familial Dyslipidemias in Patients with Premature
Coronary Heart Disease (EUFAM) study cohort is comprised of the Finnish familial combined hyperlipidemia families. 21 The families in EUFAM study were identified via probands admitted to Finnish university hospitals with a diagnosis of premature coronary heart disease. For the lipidomic profiling, 1,039 EUFAM participants for which serum samples were available were included (Supplementary Table 1 ).
FINRISK:
The Finnish National FINRISK study is a population-based survey conducted every 5 years since 1972 (detailed in Supplementary Data). 22 Lipidomic profiling was performed for 1, 142 participants that were randomly selected from the FINRISK 2012 survey ( Supplementary Table 1 ).
Finnish Biobank:
The Finnish Biobank data is composed of 47,980 Finnish participants with 807 phenotypes derived from ICD codes in Finnish national hospital registries and cause-of-death registry as a part of FinnGen project.
UK Biobank:
The UK Biobank data is comprised of >500,000 participants based in UK and aged 40-69 years, annotated for over 2,000 phenotypes. 23 The PheWAS analyses in the present study included 408,961 samples from white British participants.
Written informed consent was obtained from all the study participants. The study protocols were approved by the ethics committees of the participating centers. The study was conducted in accordance with the principles of the Helsinki declaration.
Lipidomic profiling
Mass Table 2 ) detected consistently in three batches were included in further analyses. The total amounts of lipid classes were calculated by summing up respective lipid species.
The measured concentrations of the lipid species and calculated class total were transformed to normal distribution by rank-based inverse normal transformation.
Genotyping and imputation
Genotyping for both EUFAM and FINRISK cohorts was performed using the HumanCoreExome BeadChip (Illumina Inc., San Diego, CA, USA). Genotype data underwent stringent quality control (QC) before imputation using an in-house QC pipeline (Supplementary Data). Imputation was performed using IMPUTE2, 24 which used two population specific reference panels of 2,690 high coverage whole-genome and 5,093 high coverage whole exome sequence data. Variants with imputation info score <0.70 were filtered out. After QC on lipidomic profiles and imputed variants, all subsequent analyses included 2045 individuals and ~9.3 million variants with MAF >0.005 that were available in both cohorts.
Genotyping of the Finnish Biobank samples was performed using arrays from Illumina and Affymetrix (Santa Clara, CA, USA) and custom-designed Affymetrix array for the FinnGen project.
Quality control and imputation were performed using the same pipeline as described above.
Genotyping for the majority of the UK Biobank participants was done using the Affymetrix UK Biobank Axiom Array, while a subset of participants was genotyped using the Affymetrix UK BiLEVE Axiom Array. Details about the quality control and imputation of UK Biobank cohort are described earlier. 25 
Heritability estimates and genetic correlations
For heritability and genetic correlation estimation, rank-based inverse transformed measures of lipid species, computed separately for the EUFAM and FINRISK cohorts, were combined to increase statistical power. The residuals of transformed measures after regressing for age, sex, first ten principal components (PCs) of genetic population structure, lipid medication, hormone replacement therapy, thyroid condition and type 2 diabetes were used as phenotypes. A genetic relationship matrix (GRM) was generated using GCTA, 26 after removing variants with missingness >10% and MAF <0.005. The generated GRM was then used to estimate heritability using variance component analysis and genetic correlations using bivariate linear mixed model as implemented in biMM. 27 The heritability estimates of lipid species in different groups were compared using Mann-Whitney U test. The phenotypic correlations based on the plasma levels between all the pairs of the lipid species and traditional lipid measures were calculated using Pearson's correlation coefficient. The heatmaps and hierarchical clustering based on genetic and phenotypic correlations were generated using heatmap.2 in R.
Lipidomics GWAS and meta-analysis
We performed univariate association tests for 141 individual lipid species, 12 total lipid classes and 4 traditional lipid measures (HDL-C, LDL-C, total cholesterol and triglycerides), in all batches to control for possible batch effects and combined the summary statistics by meta-analysis. The association analyses for the EUFAM cohort were performed using linear mixed models including the above-mentioned covariates as fixed effects and kinship matrix as random effect as implemented in MMM. 28 The kinship matrices for the GWAS analyses were computed separately for each chromosome to include the variants from the other chromosomes using directly genotyped variants with MAF >0.01 and missingness <2%. The FINRISK cohort was analyzed with linear regression model adjusting for age, sex, first ten PCs, lipid medication and diabetes using SNPTEST v2.5. 29 Meta-analyses were performed using the inverse variance weighted method for fixed effects adjusted for genomic inflation factor in METAL. 30 In addition, analyses adjusting for the traditional lipid measures (in addition to above-mentioned covariates) were also performed for the identified variants to determine the independent effect on lipid species.
Test statistics were adjusted for λ values if >1.0 before meta-analyses. Genomic inflation factor (λ) ranged from 0.98-1.19 across the batches whereas the final λ values for meta-analysis ranged from 0.998 to 1.045 (Supplementary Table 3 ). Associations with P value <5.0×10 -8 and consistent in direction of effect in all three batches were considered significant. Variants were designated as novel if not located within 1Mb of any previously reported variants for lipids (any of the traditional lipid measures and molecular lipid species); and as independent signal in known locus if located within 1 Mb but r 2 <0.20 with the previous lead variants and confirmed by conditional analysis. Variants with the strongest association in the identified lipid species loci was identified as the lead variants and were annotated to the nearest gene for the new loci.
PheWAS
We identified 95 disease phenotypes that have previously been linked to lipid levels including cardiometabolic, psychiatric and gastrointestinal disorders from the derived phenotypes in the Finnish Biobank. We manually mapped 44 of these 95 phenotypes to UK Biobank phenotypes (Supplementary Table 4 ). For the Finnish cohort, the associations between the 35 lead variants from the identified loci and these 44 phenotypes were obtained from the ongoing PheWAS as a part of the FinnGen project. The associations were tested using saddle point approximation method adjusting for age, sex, and first 10 PCs as implemented in SPAtest R package. 31 The association between these 44 phenotypes and 35 lead variants in UK Biobank were obtained from Zhou et al.
that were tested using logistic mixed model in SAIGE with a saddle point approximation and adjusting for first four principal components, age and sex (https://www.leelabsg.org/resources). 32 In addition, associations with obesity and body mass index (BMI) were also tested using logistic and linear regression models respectively with the same covariates as mentioned above, both for Finnish and UK Biobank cohorts. Individuals with BMI ≥30kg/m 2 were categorized as obese. Metaanalyses of both cohorts were performed using the inverse variance weighted method for fixed effects model in METAL. All the PheWAS associations with false discovery rate (FDR) <5% evaluated using the Benjamini-Hochberg method were considered significant.
Variance explained
To determine the variance explained by the known loci for traditional lipid measures, we included all the lead variants with MAF >0.005 in 250 genomic loci that have previously been associated with one or more of the four traditional lipid measures (Supplementary Table 5 ). Of the 636 reported variants, 557 variants with MAF >0.005 (including six proxies) were available in our QC passed imputed genotype data. A genetic relationship matrix (GRM) based on these 557 variants was generated using GCTA that was used to determine the variance in plasma levels of all lipid species explained by the known variants using variance component analysis in biMM.
Results
Genetic contribution to lipidome
SNP based heritability estimates ranged from 0.10 to 0.54 (Figure 2A , Supplementary Table 2) , with considerable variation across lipid classes ( Figure 2B ), with similar trends as reported previously. 33, 34 Ceramides (CER) showed the greatest estimated heritability (median=0.30, IQR=0.09) whereas phosphatidylinositols (PIs) showed the least heritability (median=0.19, IQR=0.045). Sphingolipids had higher heritability than glycerolipids ranging from 0.27 to 0.41 ( Figure 2B ), which is similar to a previous study that reported higher heritability for sphingolipids ranging from 0.28 to 0.53 estimated based on pedigrees. 33 Lipids containing polyunsaturated fatty acids, particularly C20:4, C20:5 and C22:6, had significantly higher heritability compared to other lipid species ( Figure 2C ). Table 2 ).
Moreover, longer, polyunsaturated lipids (those with four or more double bonds) had strong genetic correlations with each other than with other lipid species ( Supplementary Figure 1 , Supplementary   Table 6 ). This can be seen in the hierarchical clustering based on genetic correlations that segregate TAG subspecies into two clusters based on carbon content and degree of unsaturation ( Figure 2D ).
These patterns were not seen in phenotypic correlations that were estimated based on the plasma levels of lipid species (Supplementary Figure 2 ).
We observed low phenotypic and genetic correlation between traditional lipids and molecular lipid species, except strong positive genetic correlations of triglycerides with TAG and DAG subspecies (average r=0.88) ( Figure 3 ). However, triglycerides had low genetic correlation with other lipid species (average (abs) r= 0.26). HDL-C and LDL-C levels had low genetic and phenotypic correlations with most of the lipid species (Figure 3 , Supplementary Table 6 ). This implies that genetic variants associated with traditional lipid measures would fail to capture the variations in plasma levels of many lipid subspecies. Consistently, all of the known lipid variants explained 2% to 21% of variances in plasma levels of various lipid species, with the least variance accounting for LPCs ( Figure 3 ).
It is to be noted that this sample size might not provide sufficient power for heritability estimations in unrelated samples. However, our study also included the family samples which provides higher statistical power in heritability estimation than unrelated samples. Moreover, lipid species with genome-wide significant association had higher heritability estimates compared to the lipid species with no significant association (Supplementary Figure 3 ).
Genetic architecture of lipidome
We found 3,754 associations between 820 variants located within 35 genomic loci (1MB blocks) and 74 lipid species from 11 lipid classes at genome-wide significance level (P<5.0x10 -8 )
( Supplementary Table 7 ). These included 37 new locus-lipid species pair associations ( Figure 4 ). Figure 4 ). In line with our observation of higher heritability for lipids with C20:4, C20:5 or C22:6 acyl chains, we detected associations for 18 out of 21 lipids with these acyl chains. Moreover, 11 out of 35 identified loci were associated with at least one of the polyunsaturated lipids. The genome-wide association statistics for all lipid species are available on the web-based database (http://35.205.141.92) for mining and visualization.
Among the 35 identified loci, 15 loci were located in genomic regions not previously reported for any lipid measure or related metabolite, and 9 loci were located near known loci for lipids but independent of any previously reported variant ( Supplementary Table 8 ). Of these 24 new loci, 8 loci (ROCK1, PTPRN2, MAF, COL5A1, SYT1, DHRS12, TMEM86B and BLK) were located in or near genes that are biologically related to lipid/glucose metabolic pathways suggesting biological significance. The lead variants with the most significant SNP-lipid species associations at the identified loci are presented in Supplementary Table 8 , with their genotype-phenotype relationships in Supplementary Figure 4 . The strongest new association was at an intronic variant rs151223356 near ROCK1 with short acyl-chain LPC(14:0,0) (P=1.9x10 -10 ). The SNP is located near ABHD3 locus which has previously been shown to associate with a phosphatidylcholine species PC(32:2;0), 18 but the identified variant is independent of all previously reported variants within 1 Mb of the region (r2<0.01 and P condtional =2.3x10 -10 ). ROCK1 encodes for a serine/threonine kinase that plays key role in glucose metabolism and has previously been implicated in CVD and diabetes pathogenesis. 35, 36 We also identified new locus-lipid species pair associations at previously reported lipid loci, revealing their specific associations. For example, at ABCG5/8, a previously known loci for total cholesterol, LDL-C and CE in LDL, 11, 16 we found a novel association of ABCG5/8 with CE(20:2;0) (P=3.9x10 -10 ). At LPL, previously associated with plasma TG levels, 11 Moreover, we replicated previous associations of FADS2, SYNE2, LIPC, GLTPD2, LASS4 and MBOAT7, [13] [14] [15] [16] [17] [18] [19] [20] either with the same lipid species or the same lipid class. and hence increased dihomo-gamma-linolenic acid (C20:3, n-6) ( Figure 5 ). Interestingly, FADS2
Lipid species associated loci and metabolic pathways
rs28456-G decreases FADS1 expression that might reduce delta 5 desaturation and subsequently resulting in decreased arachidonic acid (C20:4, n-5), eicosapentaenoic acid (C20:5, n-3), and docosahexaenoic acid (C22:6, n-3).
Furthermore, we found that APOA5 rs964184-C and LPL rs964184-T were associated with reduced levels of medium length TAGs (C50 to C56), with strongest associations with TAG(52:3;0). The striking similar patterns of associations of APOA5 rs964184-C and LPL rs11570891-T with TAG species suggest that both these variants might lead to more efficient hydrolysis of medium length TAGs ( Figure 5 ). To test this, we determined the effect of LPL rs11570891-T on LPL enzymatic activity and relationship between LPL activity and TAG subspecies using post-heparin LPL measured in EUFAM cohort. We found that LPL rs11570891-T (an eQTL increasing LPL expression) was associated with the increased LPL activity which in turn was associated with TAG species with higher effect on medium length TAGs than other TAGs ( Figure 5 ).
SYNGR1 rs186680008-C showed stronger associations with decreased levels of lipid species with C20:3 acyl chain from different lipid classes including CEs, PCs and PCOs (Supplementary Figure 5 ). This suggests that SYNGR1 rs18680008-C might have role in negative regulation of either desaturation of linoleic acid (C18:2, n-6) or elongation of gamma linoleic acid (C18:3, n-6)
which could lead to decreased levels of lipids with C20:3 acyl chain, presumably dihomo-gammalinolenic acid (DGLA; C20:3, n-6) ( Figure 5 ). PTPRN2 rs10281741-G and MIR100HG rs10790495-G showed very similar patterns of associations with reduced levels of long polyunsaturated TAG species, suggesting their role in negative regulation of either elongation and desaturation of fatty acids or incorporation of long chain unsaturated fatty acids during TAG biosynthesis.
Lipid species associated loci and disease risks
PheWAS revealed associations of lead variants from six lipid species associated loci (APOA5, ABCG5/8, BLK, LPL, FADS2 and SPTLC3) with at least one of the clinical endpoints (FDR<5%) ( Table 2 , Supplementary Table 9 ). These included novel associations of variants at FADS2, BLK and SPTLC3 with various disease outcomes. FADS1-2-3 is a well-known lipid modifying locus, however, like many other known lipid loci, its effects on CVD risk has been unclear. We found association of FADS2 rs28456-G with lower risk of phlebitis and thrombophlebitis.
The PC(16:0;0-16:0;0) associated locus-BLK (rs1478898-A), which is an eQTL for BLK, showed association with decreased risk of obesity and hypertension, and increased risk of gallbladder disorders. In addition to its role in B-cell receptor signaling and B-cell development,
BLK stimulates insulin synthesis and secretion in response to glucose and enhances the expression of several pancreatic beta-cell transcription factors. 37 Consistent to its physiological roles, BLK has previously been implicated in autoimmune diseases such as systemic lupus erythematosus, 38 maturity-onset diabetes of the young (MODY), 37 and hypertension, 39 however its role in obesity and gallbladder disorder has not been described before.
SPTLC3 rs364585-G (associated with reduced levels of ceramides) showed association with reduced risk of gallbladder disorders (cholelithiasis). SPTLC3 is a rate-limiting enzyme involved in ceramide biosynthesis. Inhibition of ceramides biosynthesis has been suggested to suppress the gallstones formation in animal model, 40 however the relationship has not been explored in humans yet. Our results suggest that rs364585-G, which is an eQTL for SPTLC3 leading to reduced expression of SPTLC3, might modulate the risk of gallbladder disorders through its effect on ceramide biosynthesis. Altogether, our PheWAS results suggest potential disease susceptibility genes that warrant further investigation to validate and understand their role in disease outcomes.
Lipidomics provide higher statistical power
As intermediate phenotypes are known to provide more statistical power, we assessed whether the lipid species could help to detect genetic associations with greater power than traditional lipid measures using variants previously identified for traditional lipid measures (number of variants=557). We found that molecular lipid species have much stronger associations than traditional lipid measures with the same sample size, except for well-known APOE and CETP ( Figure 6 , Supplementary Table 10 ). The associations were several orders of magnitudes stronger for the variants in or near genes involved in lipid metabolism such as FADS1-2-3, LIPC, ABCG5/8, SGPP1, SPTLC3. This shows that the lipidomics provides higher chances to identify lipidmodulating variants, particularly the ones with direct role in lipid metabolism, with much smaller sample size than traditional lipid measures.
Discussion
Our study integrates lipidome, genome and phenome to reveal detailed description of genetic regulation of lipid metabolism and its effect on disease risk. To the best of our knowledge, this is the first large-scale study of genetics of lipidomics presenting the SNP based heritability, genetic sharing of the lipid species, and new genomic loci associated with one or several lipid species and disease risks in humans. The detailed profiling also provided clues to probable molecular mechanisms for genetic variants both at new and previously reported loci.
The results presented here allow us to draw several conclusions. First, despite the influence of dietary intake on the circulatory levels of lipids, plasma levels of lipid species are found to be heritable, suggesting considerable role of endogenous regulation in lipid metabolism. Importantly, genetic mechanisms seem not to regulate all lipid species in a lipid class in the same way, as also observed in recent mice lipidomics studies. 41, 42 Longer and more unsaturated lipid species from different lipid classes clearly display a greater genetic sharing. These observations are consistent with a previous study based on family pedigree. 33 Our finding is important in the light of the proposed role of lipids containing PUFAs in CVD, diabetes, and neurological disorders. [43] [44] [45] Identification of genetic factors regulating these particular lipids is important for understanding the subtleties of lipid metabolism and devising disease preventive strategies; including dietary interventions for these common complex diseases that cause an enormous public health burden globally. Our study provides multiple leads in this direction by identifying 11 genomic loci (KLHL17, APOA1, CD33, SHTN1, FADS2, LIPC, MBOAT7, MIR100HG, PTPRN1, and TMEM86B) associated with long, polyunsaturated lipids. Of these, FADS2, APOA1, and LPL variants were also associated with cardiovascular related phenotypes in our PheWAS analysis ( Figure 5 ). We discuss below how identification of genetic variants in these lipid species associated loci has helped us to provide new insights to their role in lipid metabolism.
Second, we identified genetic variants associated with 74 lipid species from 11 lipid classes.
Individual lipid species from several lipid classes including CERs, CEs, TAGs, and PCs have been shown to predict risk for CVD and diabetes. [4] [5] [6] [7] [8] [9] [10] This knowledge can directly fuel studies on disease markers or drug target discovery. For example, Cer(d18:1/24:0) is recently reported to be associated with increased risk of CVD events. 46 We have identified a variant associated with Cer(42:1;2) (this species presumably includes Cer(d18:1/24:0) molecular species) near ZNF385D. The ZNF385D
rs13070110-C was associated with increased levels of Cer(42:1;2). We also observed nominal association of rs13070110-C with increased risk of arterial and venous thrombosis (Supplementary Table 9 ). CEs have also been reported to modulate the risk of CVD events. 4, 8 Our study revealed three loci associated with CEs, including two novel loci-ABCG5/8 and SYNGR1. The rs76866386-C at ABCG5/8, which codes for ABC sterol transporters G5 and G8, has previously been associated with TC, LDL-C and CEs in LDL, 11, 16 however we identified a specific association of rs76866386-C with reduced level of cholesteryl ester species CE(20:2;0). CE(20:2;0) has been shown to be positively associated with high LDL-C, 47 suggesting that the previously observed associations of help us understand the effects of genetic variants or genes in specific metabolic pathways at molecular level. Genetic variants at FADS gene cluster have been consistently reported to be associated with omega-3 and omega-6 fatty acids levels with inverse effects on different PUFAs, however, its mechanism has not been fully deciphered. Linoleic acid and alpha-linolenic acid are essential fatty acids and substrates for delta-6 desaturation by FADS2. 48 This desaturation step generates gamma-linolenic acid and stearidonic acid that by elongation yields dihomo-gammalinolenic acid and eicosatetraenoic acid ( Figure 5 ). Further, delta-5 desaturation of dihomo-gammalinolenic acid by FADS1 generates arachidonic acid and eicosapentaenoic acid. Subsequent elongations and desaturations generate docosatetraenoic acid, docosapentaenoic acid, and docosahexaenoic acid. Thus, as depicted in Figure 5 , the inverse efffects of FADS2 rs28456-G on codes for long non-coding RNAs that act as regulators of cell proliferation. 50 The MIR100HG
rs10790495 is an eQTL for the heat shock protein HSPA8 that also has a role in cell proliferation. 51 However, it is not known if PTPRN2 and MIR100HG or HSPA8 have any role in lipid metabolism.
Our results suggest that these variants might have role in negative regulation of either elongation and desaturation of fatty acids or incorporation of long chain unsaturated fatty acids during TAG biosynthesis.
Fourth, our results point to probable risk/protective variants for diseases, highlighting the potential of using detailed lipidomics profiles in disease gene mapping. Two lipid species associated loci-BLK and SPTLC3 were found to be associated with cholelithiasis (gallstones). BLK was also identified as a new susceptibility locus for obesity in the present study. Cholelithiasis is one of the most prevalent gastrointestinal diseases with up to 15% prevalence in adult populations. Although up to two thirds of patients do not suffer any symptoms, cholelithiasis is the most significant risk factor for acute cholecystitis. 52 Risk factors of cholelithiasis include obesity, hyperlipidemia and type 2 diabetes. Also, the pathogenesis of cholelithiasis is now recognized to be influenced by the immune system. 53 Owing to its role in immune response, insulin synthesis and insulin secretion, BLK seems to be a potential risk modifying gene for obesity and cholelithiasis. Relationship between ceramides and cholelithiasis has also been suggested previously, 40 and given the role of SPTLC3 in ceramide biosynthesis, the SPTLC3 variant might influence the risk for gallstones.
However, the associations of these variants with disease risks warrant further investigation.
Finally, we show that genetic investigation utilizing only those lipid measures that are traditionally used in routine clinical work would fail to capture the association with molecular lipid species which are potential independent disease risk factors. For example, LPCs and PCs have previously been associated with incident coronary heart disease risk. [4] [5] [6] But we show that these lipid measures have very low phenotypic and genotypic correlations with traditional lipid measures and known variants for traditional lipid measures explain only a small percentage of variance in their plasma levels. This again highlights the potential of lipidomic profiles in disease gene identification. We also demonstrate that individual lipid species have stronger statistical power to detect the associations compared to the traditional lipid measures at all known lead variants using the same dataset. These findings suggest that lipidomic profiles capture information beyond standard lipid measures and provide opportunity to identify additional genetic variants influencing lipid metabolism.
Our study had some potential limitations. To the best of our knowledge, the present study is the largest genetic screen of lipidomic variation, but larger cohorts are needed to achieve full understanding of the genetic regulation of detailed lipid metabolism. The EUFAM cohort samples were from fasting state whereas the FINRISK cohort samples were semi-fasting. This does not seem to have substantial effect on lipidomic profiles as we demonstrated similar lipidomic profiles for dyslipidemias from the EUFAM and FINRISK cohorts. 47 Moreover, the recent guidelines from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine recommends non-fasting blood samples for assessment of plasma lipid profiles. 54 The UK Biobank cohort is reported to have "healthy volunteer" effect, 55 which may affect the PheWAS results. However, given the large sample size, the selection bias is unlikely to have substantial effect on genetic case-control association analyses. Furthermore, lipidomic profiles were measured in whole plasma comprising of all lipoprotein classes and particle sizes, which does not provide information at the level of individual lipoprotein subclasses and limits our ability to gain detailed mechanistic insights. We also excluded poorly detected lipid species from all the analyses to ensure high data quality that narrowed the spectrum of lipidomic profiles. Further advances in lipidomics platforms might help to capture more comprehensive and complete lipidomic profiles, including the position of fatty acyl chains in glycerol backbone of TAGs and glycerophospholipids and detection of sphingosine-1-P species and several other species, that would allow to overcome these limitations.
In conclusion, our study demonstrates that lipidomics enable deeper insights to the genetic regulation of lipid metabolism than clinically used lipid measures, which in turn might help guide future biomarker and drug target discovery and disease prevention. Supplementary Table 9 . The points on the plots are color coded by the lipid classes in upper panel and traditional lipid measure in lower panel.
